Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study

The surprising results published by FIRE-3 revealed that the overall survival (OS) of RAS wild-type metastatic colorectal cancer (mCRC) patients treated with Cetuximab(Cmab) and FOLFIRI combination was prolonged to 33.1 months. The substantial increase in testing and treatment costs, however, impose...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Biol Ther
Main Authors: Wen, Feng, Yang, Yu, Zhang, Pengfei, Zhang, Jian, Zhou, Jing, Tang, Ruilei, Chen, Hongdou, Zheng, Hanrui, Fu, Ping, Li, Qiu
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2015
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4846122/
https://ncbi.nlm.nih.gov/pubmed/26418570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2015.1095398
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados